Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Nektar Therapeutics(NKTR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NKTR
09/24/2026: NKTR (3-star) is currently NOT-A-BUY. Pass it for now.
Nektar Therapeutics is a clinical-stage biotechnology company that leverages proprietary polymer chemistry to develop therapeutics for immunology and oncology. The company’s core strength lies in its specialized platform technology, which it uses to pursue niche medical treatments in high-need areas. Its primary investment story hinges on the success of late-stage clinical candidates like REZPEG, which represent its main growth opportunity. However, investors face substantial risks, including a high cash burn rate, potential clinical trial failures, and intense competition from large-cap pharmaceutical firms. The stock is best suited for risk-tolerant, growth-oriented investors who are capable of monitoring clinical data readouts and long-term regulatory developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Investors focused on long-term growth may find the company's clinical-stage pipeline attractive, though the path to commercialization is uncertain. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find the stock attractive during periods of positive clinical news flow, provided the upward trend is confirmed. |
| Value investor | Weak fit | The lack of consistent earnings and the clinical nature of the business make it a poor fit for traditional value-based investment strategies. |
| Dividend investor | Weak fit | Nektar does not pay a dividend and requires significant capital for development, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | The company's reliance on successful drug development creates high volatility, which is generally unsuitable for low-risk investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks often experience sharp price swings based on trial results and regulatory news. |
| Valuation risk | Medium / high | Valuations are difficult to anchor without commercial revenue, making stock prices sensitive to shifts in market sentiment. |
| Competition risk (Large-cap pharma) | High | Nektar faces significant pressure from well-funded rivals that can outspend and out-market competing therapies. |
| Business quality | Medium | While the platform technology is well-regarded, the business relies on high-risk, long-cycle R&D success. |
| Dividend income | Low / none | No dividends are paid, so investors rely entirely on capital appreciation. |
| Execution risk | High | Successful clinical execution and regulatory approval are the singular most important factors for the company's future value. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 255.59% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.03B USD | Price to earnings Ratio - | 1Y Target Price 141.4 |
Price to earnings Ratio - | 1Y Target Price 141.4 | ||
Volume (30-day avg) 936.3K shares | Beta 1.15 | 52 Weeks Range 33.40 - 109.00 | Updated Date 09/24/2026 |
52 Weeks Range 33.40 - 109.00 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.29 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Payments from partners for the development of drug candidates and intellectual property licensing fees. | Revenue is unpredictable and driven by research achievements rather than steady product sales. |
| Royalties | Legacy royalty streams from previously out-licensed products developed using Nektar's platform. | This provides a small but established base of income, though it is not the company's primary focus. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 34.01 | Enterprise Value 1.36B | Price to Sales(TTM) 37.14 |
Enterprise Value 1.36B | Price to Sales(TTM) 37.14 | ||
Enterprise Value to Revenue 24.99 | Enterprise Value to EBITDA -6.5 | Shares Outstanding 34.14M | Shares Floating 28.54M |
Shares Outstanding 34.14M | Shares Floating 28.54M | ||
Percent Insiders 0.35 | Percent Institutions 106.92 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Nektar Therapeutics
Exchange NASDAQ | Headquarters San Francisco, CA, United States | ||
IPO Launch date 1994-05-03 | CEO, President & Director Mr. Howard W. Robin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | Website https://www.nektar.com |
Full time employees 63 | Website https://www.nektar.com | ||
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.